Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial

Adam Christian Vilmar, Eric Santoni-Rugiu, Jens Benn Sørensen

Research output: Contribution to journalJournal articleResearchpeer-review

39 Citations (Scopus)

Abstract

Platinum-based doublets are the cornerstone of treatment in advanced non-small-cell lung cancer (NSCLC) and often include vinorelbine or taxanes. A predictive biomarker is greatly needed to select chemotherapy-sensitive patients for these microtubule-interfering agents. Class III ß-tubulin (TUBB3) has been shown of value in NSCLC, but evidence is not uniform. Accordingly, we explored the predictive role of TUBB3 in advanced NSCLC.
Original languageEnglish
JournalClinical Cancer Research
Volume17
Issue number15
Pages (from-to)5205-14
Number of pages10
ISSN1078-0432
DOIs
Publication statusPublished - 2011

Cite this